New strategies to address drug-drug interactions involving OATPs

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 1, 2007, Pages 74-83

  Poirier, Agnès ^a   Funk, Christoph ^a   Lavé, Thierry ^a   Noé, Johannes ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug drug interactions; Gemfibrozil; Modeling; OATP; PBPK; Statins; Transporters

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; DIGOXIN; ERYTHROMYCIN; FEXOFENADINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; METHOTREXATE; MEVINOLIN; NATEGLINIDE; ORGANIC ANION TRANSPORTER; PACLITAXEL; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TEICOPLANIN; TROGLITAZONE;

ACTIVE TRANSPORT; COMPUTER MODEL; COMPUTER PROGRAM; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MUSCLE TOXICITY; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PROTEIN INTERACTION; RHABDOMYOLYSIS; TOXICITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, THEORETICAL; ORGANIC ANION TRANSPORTERS; RIFAMPIN; TECHNOLOGY, PHARMACEUTICAL;

EID: 33947323721     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM: Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharmacol (2006) 3(1):62-69. • FDA proposal for the evaluation of MDR1-mediated DDIs.
2. Kunta JR, Sinko PJ: Intestinal drug transporters: In vivo function and clinical importance. Curr Drug Metab (2004) 5(1):109-124.
3. DuBuske LM: The role of P-glycoprotein and organic aniontransporting polypeptides in drug interactions. Drug Saf (2005) 28(9):789-801.
4. Endres CJ, Hsiao P, Chung FS, Unadkat JD: The role of transporters in drug interactions. Eur J Pharm Sci (2006) 27(5):501-517.
5. Chandra P, Brouwer KL: The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm Res (2004) 21(5):719-735.
6. Charatan F: Bayer decides to withdraw cholesterol lowering drug. Br Med J (2001) 323(7309):359.
7. Smith NF, Figg WD, Sparreboom A: Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol (2005) 1(3):429-445.
8. Hagenbuch B, Meier PJ: Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch (2004) 447(5):653-665. • All six human and rat OATP families are described including gene location, new nomenclature and properties.
9. van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK: Drug uptake systems in liver and kidney. Curr Drug Metab (2003) 4(3):185-211.
10. m values and associated references. It also focuses on polymorphisms and PK/PD clinical consequences.
11. Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M: Uptake of rosuvastatin by isolated rat hepatocytes: Comparison with pravastatin. Xenobiotica (2003) 33(4):379-388.
12. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology (2006) 130(6):1793-1806. • A thorough study of rosuvastatin hepatic transport in human and rat, reporting on transporters and their degree of involvement, and pharmacogenomics of in vitro DDI with gemfibrozil and cyclosporine A for each transporter.
13. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther (2004) 311(1):139-146.
14. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther (2003) 306(2):703-708.
15. Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H, Sugiyama Y: In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. Drug Metab Dispos (2004) 32(12):1468-1475.
16. Noe J, Portmann R, Brun M, Funk C: Substrate dependent drug-drug interactions between gemfibrozil, fluvastatin and other substrates on OATP1B1 and OATP2B1. Drug Metab Dispos (2006): manuscript submitted. • Details of OATP1B1's two binding sites, and their inhibitors and substrates are reported. The data within is very important for planning in vitro experiments.
17. Launay-Vacher V, Izzedine H, Deray G: Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol (2005) 101(1):9-17.
18. Tiwari A, Bansal V, Chugh A, Mookhtiar K: Statins and myotoxicity: A therapeutic limitation. Expert Opin Drug Safety (2006) 5(5):651-666.
19. Klaassen CD, Slitt AL: Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab (2005) 6(4):309-328.
20. Kullak-Ublick GA, Stieger B, Meier PJ: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology (2004) 126(1):322-342.
21. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O: Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos (2006) 34(10):1756-1763.
22. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther (2006) 79(5):419-426.
23. Kerb R: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett (2006) 234(1):4-33. • Details all drug transporters polymorphisms and the pharmacological relevance of the genetic variants.
24. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol (1995) 76(2):80A-83A.
25. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 68(2):122-129.
26. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos (2006) 34(7):1229-1236. • Study of pitavastatin hepatic transport, the transporters involved and the level of transport. Thirty-four drugs were tested in vitro for DDI with pitavastatin in OATP1B1-expressing cells. Comparisons between in vitro DDI and effective clinical DDI were also predicted.
27. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transportermediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther (2003) 304(2):610-616.
28. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ: Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther (2005) 78(2):154-167.
29. Igel M, Sudhop T, von Bergmann K: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol (2001) 57(5):357-364.
30. Sirtori CR: Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther (1993) 60(3):431-459.
31. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther (2001) 69(5):340-345.
32. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther (2002) 301(3):1042-1051.
33. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther (2002) 72(6):685-691.
34. Shitara Y, Hirano M, Sato H, Sugiyama Y: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther (2004) 311(1):228-236.
35. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos (2001) 29(11):1359-1361.
36. Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T et al: Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and Pglycoprotein-mediated transport. Xenobiotica (2005) 35(7):737-753. • All fibrates were tested in vitro for inhibition of OATP1B1, MRP2 and MDR1. Gemfibrozil appears to be the only fibrate to have a potential to cause DDI by inhibiting OATP1B1 at clinically relevant concentrations.
37. Mukhtar RY, Reid J, Reckless JP: Pitavastatin. Int J Clin Pract (2005) 59(2):239-252.
38. Igel M, Sudhop T, von Bergmann K: Pharmacology of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol (2002) 42(8):835-845.
39. Schachter M: Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol (2005) 19(1):117-125.
40. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y: Uptake is the ratelimiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res (1996) 13(10):1559-1564.
41. Mathew P, Cuddy T, Tracewell WG, Salazar D: An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther (2004) 75(2):33.
42. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther (2003) 73(6):538-544.
43. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther (2004) 75(5):455-463.
44. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K: A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet (2004) 19(6):453-455.
45. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics Genomics (2005) 15(5):303-309.
46. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y: Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol (2004) 66(3):450-459.
47. Spears KJ, Ross J, Stenhouse A, Ward CJ, Goh LB, Wolf CR, Morgan P, Ayrton A, Friedberg TH: Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol (2005) 69(3):415-423.
48. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther (2005) 314(3):1059-1067.
49. Kopplow K, Letschert K, Konig J, Walter B, Keppler D: Human hepatobiliary transport of organic anions analyzed by quadrupletransfected cells. Mol Pharmacol (2005) 68(4):1031-1038.
50. Rippin SJ, Hagenbuch B, Meier PJ, Stieger B: Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology (2001) 33(4):776-782.
51. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y: Function of uptake transporters for taurocholate and estradiol 17β-D- glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet (2003) 18(1):33-41.
52. Bi YA, Kazolias DC, Duignan DB: Use of cryopreserved human hepatocytes in sandwich-culture to measure hepatobiliary transport. Drug Metab Dispos (2006) 34(9):1658-1665.
53. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, Brouwer KL: P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: Relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res (2004) 21(7):1294-1302.
54. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O: Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci (2006) 28(1-2):109-117.
55. Halwachs S, Kneuer C, Honscha W: Endogenous expression of liverspecific drug transporters for organic anions in the rat hepatocytoma fusion cell line HPCT-1E3. Eur J Cell Biol (2005) 84(7):677-686.
56. Chang C, Pang KS, Swaan PW, Ekins S: Comparative pharmacophore modeling of organic anion transporting polypeptides: A meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 314(2):533-541.
57. Yarim M, Moro S, Huber R, Meier PJ, Kaseda C, Kashima T, Hagenbuch B, Folkers G: Application of QSAR analysis to organic anion transporting polypeptide 1a5 (Oatp1a5) substrates. Bioorg Med Chem (2005) 13(2):463-471.
58. Saville BA, Gray MR, Tam YK: Models of hepatic drug elimination. Drug Metab Rev (1992) 24(1):49-88.
59. Robinson PJ: Physiologically based liver modeling and risk assessment. Risk Anal (1992) 12(1):139-148.
60. Wilkinson GR: Clearance approaches in pharmacology. Pharmacol Rev (1987) 39(1):1-47.
61. Shitara Y, Sugiyama Y: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther (2006) 112(1):71-105. • Extended review on statin pharmacology and pharmacokinetics, and the creation of models of the elimination of statins from the liver, and OATP- and CYP-mediated DDI.
62. Hatanaka T, Honda S, Sasaki S, Katayama K, Koizumi T: Pharmacokinetic and pharmacodynamic evaluation for tissueselective inhibition of cholesterol synthesis by pravastatin. J Pharmacokinet Biopharm (1998) 26(3):329-347.
63. Andersen ME, Eklund CR, Mills JJ, Barton HA, Birnbaum LS: A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s. Toxicol Appl Pharmacol (1997) 144(1):135-144.
64. Deroubaix X, Coche T, Depiereux E, Feytmans E: Saturation of hepatic transport of taurocholate in rats in vivo. Am J Physiol (1991) 260(2 Pt 1):G189-G196.
65. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, DeJongh J: The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev (2001) 33(2):125-147.
66. Theil FP, Guentert TW, Haddad S, Poulin P: Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett (2003) 138(1-2):29-49.
67. Reinoso RF, Telfer BA, Brennan BS, Rowland M: Uptake of teicoplanin by isolated rat hepatocytes: Comparison with in vivo hepatic distribution. Drug Metab Dispos (2001) 29(4 Pt 1):453-459.
68. Lam JL, Okochi H, Huang Y, Benet LZ: In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos (2006) 34(8):1336-1344.
69. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, Tan ZR, Zhang WX, Yu BN, Wang D, Hu DL et al: Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol (2006) 62(5):567-572.
70. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2005) 33(3):434-439.
71. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem (1999) 274(52):37161- 37168.
72. Lau YY, Okochi H, Huang Y, Benet LZ: Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems. J Pharmacol Exp Ther (2006) 316(2):762-771.
73. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C,Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M et al: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 14(7):429-440.